Framework Agreement for the Purchase of Xenpozyme (olipudase alfa)

The purpose of this framework agreement is to ensure the supply of the medication Xenpozyme (olipudase alfa) to the hospital pharmacies of Amgros' stakeholders. Amgros, acting as the procuring entity, aims to establish a reliable supply chain for this specific pharmaceutical product. Additionally, the Regional Hospital Pharmacy of the Capital Region will undertake procurement for resale to Greenland and the Faroe Islands, indicating a broader geographical scope for distribution. Xenpozyme (olipudase alfa) is a specialized drug, and this framework agreement will facilitate efficient and potentially cost-effective procurement over a defined period. Interested pharmaceutical suppliers or distributors capable of meeting the stringent requirements for handling and supplying such medications are invited to participate. The agreement will outline terms related to quantity, delivery, quality assurance, and pricing for Xenpozyme.

This is a supplies contract in the health and medical services sector, with a focus on Hospitals and Pharmaceuticals. Located in Denmark, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.